Company
Ancestry belongs in drug-response decisions from the start.
Anukriti AI Private Limited builds population-aware pharmacogenomics tooling so drug-response risk across ancestries is understood early — and auditable throughout.
What we believe
Most evidence on how genes shape drug response comes from people of European ancestry, so risk in other populations tends to surface late, at the expensive clinical-trial stage. We treat population structure as a first-class, auditable input instead of an afterthought.
What Anukriti is — and isn’t
Anukriti is a research and education platform for population-aware pharmacogenomic interpretation. It is not a clinical diagnostic system, and its output is not medical advice. We treat honesty as a feature: we disclose known limitations, and the engine refuses when the evidence isn’t there.
Recognition & foundations
- AWS AIdeas winner — Top 20 of 10,000+ ideas across 115 countries.
- Built on 1000 Genomes, ChEMBL, RDKit, CPIC, and PharmVar.
Team
Team details are coming soon. Anukriti AI Private Limited is an early-stage company; founder and team information will be published here once finalised.